Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;11(24):2207-2244.
doi: 10.4155/bio-2019-0271. Epub 2019 Dec 10.

2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3 - Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62)

Steven Piccoli  1 Devangi Mehta  2 Alessandra Vitaliti  3 John Allinson  4 Shashi Amur  5 Steve Eck  6 Cherie Green  7 Michael Hedrick  8 Shirley Hopper  9 Allena Ji  10 Alison Joyce  11 Virginia Litwin  12 Kevin Maher  5 Joel Mathews  13 Kun Peng  7 Afshin Safavi  14 Yow-Ming Wang  5 Yan Zhang  8 Lakshmi Amaravadi  15 Nisha Palackal  16 Sai Thankamony  8 Chris Beaver  17 Eris Bame  2 Thomas Emrich  18 Christine Grimaldi  19 Jonathan Haulenbeek  8 Alison Joyce  11 Vellalore Kakkanaiah  20 David Lanham  21 Kevin Maher  5 Andrew Mayer  1 Paul C Trampont  22 Laurent Vermet  23 Naveen Dakappagari  24 Catherine Fleener  25 Fabio Garofolo  26 Cynthia Rogers  27 Shabnam Tangri  24 Yuanxin Xu  28 Meina Liang  29 Manoj Rajadhyaksha  16 Susan Richards  10 Becky Schweighardt  30 Shobha Purushothama  2 Daniel Baltrukonis  31 Jochen Brumm  7 Elana Cherry  32 Jason Delcarpini  33 Carol Gleason  8 Susan Kirshner  5 Robert Kubiak  6 Luying Pan  34 Michael Partridge  16 João Pedras-Vasconcelos  5 Qiang Qu  35 Venke Skibeli  36 Therese Solstad Saunders  36 Roland F Staack  18 Kay Stubenrauch  18 Al Torri  16 Daniela Verthelyi  5 Haoheng Yan  5 Boris Gorovits  11 Rachel Palmer  10 Mark Milton  37 Brian Long  30 Bart Corsaro  38 Vahid Farrokhi  11 Michele Fiscella  39 Neil Henderson  40 Vibha Jawa  41 Jim McNally  34 Rocio Murphy  42 Hanspeter Waldner  43 Tong-Yuan Yang  44
Affiliations

2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3 - Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62)

Steven Piccoli et al. Bioanalysis. 2019 Dec.

Abstract

The 2019 13th Workshop on Recent Issues in Bioanalysis (WRIB) took place in New Orleans, LA, USA on April 1-5, 2019 with an attendance of over 1000 representatives from pharmaceutical/biopharmaceutical companies, biotechnology companies, contract research organizations and regulatory agencies worldwide. WRIB was once again a 5-day, week-long event - a full immersion week of bioanalysis, biomarkers, immunogenicity and gene therapy. As usual, it was specifically designed to facilitate sharing, reviewing, discussing and agreeing on approaches to address the most current issues of interest including both small- and large-molecule bioanalysis involving LCMS, hybrid LBA/LCMS, LBA cell-based/flow cytometry assays and qPCR approaches. This 2019 White Paper encompasses recommendations emerging from the extensive discussions held during the workshop and is aimed to provide the bioanalytical community with key information and practical solutions on topics and issues addressed, in an effort to enable advances in scientific excellence, improved quality and better regulatory compliance. Due to its length, the 2019 edition of this comprehensive White Paper has been divided into three parts for editorial reasons. This publication (Part 3) covers New Insights in Biomarker Assay Validation, Current & Effective Strategies for Critical Reagent Management, Flow Cytometry Validation in Drug Discovery & Development & CLSI H62, Interpretation of the 2019 FDA Immunogenicity Guidance and Gene Therapy Bioanalytical Challenges. Part 1 (Innovation in Small Molecules and Oligonucleotides & Mass Spectrometry Method Development Strategies for Large Molecule Bioanalysis) and Part 2 (Recommendations on the 2018 FDA BMV Guidance, 2019 ICH M10 BMV Draft Guideline and regulatory agencies' input on bioanalysis, biomarkers, immunogenicity and gene therapy) are published in volume 11 of Bioanalysis, issues 22 and 23 (2019), respectively.

PubMed Disclaimer

LinkOut - more resources